Opportunities and challenges in the clinical application of anticancer virotherapy.
1/5 보강
[INTRODUCTION] Oncolytic viruses (OVs) are a promising yet understudied class of therapeutic agents.
APA
Sierra-Davidson K, Cohen S, et al. (2026). Opportunities and challenges in the clinical application of anticancer virotherapy.. Expert review of anticancer therapy, 26(2), 191-203. https://doi.org/10.1080/14737140.2025.2584499
MLA
Sierra-Davidson K, et al.. "Opportunities and challenges in the clinical application of anticancer virotherapy.." Expert review of anticancer therapy, vol. 26, no. 2, 2026, pp. 191-203.
PMID
41175341 ↗
Abstract 한글 요약
[INTRODUCTION] Oncolytic viruses (OVs) are a promising yet understudied class of therapeutic agents. OVs mediate anti-tumor activity through multiple mechanisms, including direct lysis of tumor cells, local expression of therapeutic transgenes, and induction of anti-tumor immunity. In 2015, Talimogene laherparepvec (T-VEC) was approved OV for melanoma. Recent literature search and real-world experience have highlighted some of the challenges with clinical adoption of OV therapy and identified new opportunities for improving the clinical use of OVs for cancer treatment.
[AREAS COVERED] This review provides a brief overview of recent challenges and lessons learned from clinical trials and real-world data related to T-VEC and explores novel strategies for enhancing the therapeutic activity of OVs.
[EXPERT OPINION] OVs are versatile agents that can attack cancer at multiple levels. The ability to use OVs to add to defined mechanisms of anti-tumor activity, such as direct tumor cell killing, induction of anti-viral and anti-tumor immune responses, and effective delivery of therapeutic payloads, have resulted in multiple new OVs with promising early clinical data. OVs can be an especially useful tool for developing a more personalized approach to cancer treatment based on unique clinical features of patients and the molecular features of specific tumors.
[AREAS COVERED] This review provides a brief overview of recent challenges and lessons learned from clinical trials and real-world data related to T-VEC and explores novel strategies for enhancing the therapeutic activity of OVs.
[EXPERT OPINION] OVs are versatile agents that can attack cancer at multiple levels. The ability to use OVs to add to defined mechanisms of anti-tumor activity, such as direct tumor cell killing, induction of anti-viral and anti-tumor immune responses, and effective delivery of therapeutic payloads, have resulted in multiple new OVs with promising early clinical data. OVs can be an especially useful tool for developing a more personalized approach to cancer treatment based on unique clinical features of patients and the molecular features of specific tumors.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.